Recent Updates — SBEVW
Endovia Health Sciences, Inc. entered into employment agreements on August 20, 2026, appointing Brady Cobb as Interim CEO and Michael Bondurant as Interim COO. Mr. Cobb receives a $300,000 annual base salary and Mr. Bondurant $275,000. Both executives are eligible for performance bonuses tied to market capitalization milestones: $50,000 increments at $5 million and $10 million increases above the agreement date baseline by October 30 and December 31, 2026, respectively, plus a variable bonus capped at $300,000 for further gains in 2026. Mr. Cobb received 231,250 stock options and Mr. Bondurant 200,000 options, with potential RSU grants subject to shareholder approval. The company operates in the health sciences sector.
Endovia Health Sciences, Inc., formerly Splash Beverage Group, announced the establishment of Investigational New Animal Drug (INAD) File No. 14145 with the U.S. FDA for its CannEpil® veterinary development program. This milestone formally initiates regulatory engagement under a collaboration agreement with Lupvindal Biosciences Ltd. to develop CannEpil®, a cannabinoid formulation for managing cancer-related pain in companion animals, specifically targeting canine oncology. The company intends to pursue the FDA’s Minor Use / Minor Species (MUMS) designation and Conditional Approval pathway. Endovia Health Sciences operates as a diversified cannabinoid-based health sciences platform focused on pharmaceutical commercialization, FDA-regulated human and veterinary therapeutics, and consumer wellness.
Splash Beverage Group, Inc. announced a corporate name change to Endovia Health Sciences, Inc., with its common stock beginning trading under the new ticker symbol "EDVA" on the NYSE American effective August 24, 2026. This rebranding marks a strategic transformation from legacy beverage operations into a diversified cannabinoid-based health sciences platform focusing on commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and consumer wellness products. The company is advancing its CannEpil® veterinary development program by opening an Investigational New Animal Drug file with the U.S. Food and Drug Administration’s Center for Veterinary Medicine. Interim CEO Brady Cobb stated the change reflects a shift toward executing long-term strategy through international commercialization and regulated development pathways. This filing does not involve any changes to shareholder rights or require action from existing stockholders. The company operates in the health sciences and consumer wellness industry, developing cannabinoid-based pharmaceuticals and therapeutic products.
Splash Beverage Group reported a loss from continuing operations of approximately $4 million for the first half of 2026, a 64% improvement from the $11 million loss in the prior year period, driven by cost-reduction initiatives. The company is transitioning its business focus to cannabinoid health and wellness products under the new name Endovia Health Sciences, with a ticker change expected on August 24, 2026. Post-quarter strategic moves include an exclusive global license for CannEpil®, a veterinary expansion of that license via a collaboration with Lupvindol Biosciences, and preparations to relaunch CannEpil in international markets. Splash Beverage Group operates in the beverage and health sciences industry.
Splash Beverage Group, Inc. announced a corporate name change to Endovia Health Sciences, effective August 24, 2026, accompanied by a new ticker symbol "EDVA" and website launch. This rebranding reflects the company's strategic transformation from a legacy beverage business into a diversified cannabinoid health sciences platform focused on commercializing pharmaceutical assets, advancing FDA-regulated human and veterinary therapeutics, and developing innovative wellness products. The shift aims to leverage acquired intellectual property and international distribution opportunities to build long-term enterprise value through scientific innovation and disciplined execution.